Intended for healthcare professionals

Rapid response to:


Women still not being told about pregnancy risks of valproate

BMJ 2017; 358 doi: (Published 22 September 2017) Cite this as: BMJ 2017;358:j4426

Rapid Response:

Re: Women still not being told about pregnancy risks of valproate

The European Medicines Agency is to be congratulated for drawing attention to the need to provide advice to women with epilepsy on the risks of taking anti-epilepsy drugs (AEDs), sodium valproate in particular. The EMA disseminated information to several European organizations in advance and had speakers from the public, industry and from those with specialist interest in epilepsy.

Almost all UK prescribing and repeat prescribing is the responsibility of General Practitioners (GPs). This includes AEDs. Almost everyone is registered with a GP, so with some caveats, evidence from a large number of practices can be taken as representative of the population. Anonymized GP data has been used to describe the commonness of epilepsy, treated with AEDs in the UK (1%), changing trends in prescribing of AEDs, and an association between sodium valproate and major congenital malformations.1-3

Each European country is different in its system of delivery of medical care and medicine. This makes it difficult to plan and implement a ‘one-size-fits-all’ change. In some Scandinavian countries, specialists monitor and prescribe for people with epilepsy. They also record data electronically allowing them to monitor risks of AEDs, and other risks. Depression is a risk for pregnant women with a potential for consequences in their offspring. Not only does depression reduce quality of life directly, but it is in turn associated with reduced medication-adherence,4 which is another important risk in pregnancy. Depression and poor medication adherence is also associated with premature death in both men and women. 1,5 Here is the rub. Focusing on one condition, one medication, and one risk is does not deliver on the combination of risks individuals experience over time, and if it does, not efficiently.

In the UK this created the raison d’être for General Practice. Over the past thirty years, GPs have gradually acquired the confidence and competence to take on advising patients to reduce the impact and risk of death from many conditions, including cervical cancer in women and vascular disease in everyone. This required GPs and the primary care team to do additional training, and develop new services, and required additional resources, year on year. The NHS estimated it spends £175m (€235m; $268m) a year on identifying people at risk from cervical cancer, referral for closer monitoring, and, if necessary, for surgical intervention.6 Managing individual’s comorbidities and their risks through life is the new normal. And there has been a decline in the negative consequences including death, for example, from papilloma virus in women and vascular disease in everyone.

UK General Practice has become a victim of its own success. GP numbers have not expanded in tandem with their expanding role. GPs are now overwhelmed with the work of managing long-term conditions, for which they originally volunteered. In this context it is understandable if the RCGP did not respond to a specific request to speak on valproate in pregnancy. This is a shame, as the absent GP can easily become a whipping-boy, castigated by experts and activists, either for not knowing enough or for not doing enough, or both. The EMA naturally wants a quick win, with no additional funding required. Providing specific advice on valproate will require more consultation. Providing self-management advice for all people with epilepsy would require time. It would require for training and service development. And like cervical cancer prevention it would require resources.

If the EMA continues with this and other public hearings, I hope they will do more to include less specialist, but nevertheless important service providers, and that General Practice steps up. All doctors, apart from neurologists report neurophobia. Fear of not knowing enough neurology probably does act as a barrier to providing good community care. Twenty years ago, we found 55% people with epilepsy reported that their epilepsy care was provided by their GP, 11% by a hospital doctor, 19% by both and 15% by neither.7 Since then the number of neurologists has nearly tripled. One might hope that this increase is associated with specialist- monitoring for more UK people with epilepsy and with education provided for more GPs and practice nurses. A useful outcome of this exercise would be that that whoever prescribes valproates agrees to identify and provide regular advice to women and girls at risk. Better still, that policy-makers and providers start exploring how ongoing structured self-management advice might be offered to everyone with epilepsy.

1. Ridsdale L, Charlton J, Ashworth M, Richardson MP, Gulliford MC. Epilepsy mortality and risk factors for death in epilepsy: a population-based study. Br J Gen Pract. 2011;61(586):e271-e8. DOI: 10.3399/bjgp11X572463
2. Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993–2008: Cohort study using the General Practice Research Database. Seizure. 2012;21(6):466-70. DOI:
3. Petersen I, Collings S-L, McCrea RL, Nazareth I, Osborn DP, Cowen PJ, et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clin Epidemiol. 2017;9:95-103. PubMed PMID: PMC5317245.
4. Ettinger AB, Good MB, Manjunath R, Edward Faught R, Bancroft T. The relationship of depression to antiepileptic drug adherence and quality of life in epilepsy. Epilepsy & Behav. 2014;36(Supplement C):138-43. DOI:
5. Fazel S, Wolf A, Långström N, Newton CR, Lichtenstein P. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet. 2013;382(9905):1646-54. DOI:
6. Public Health England. NHS cervical screening programme. 2015 [cited 2017 Sep 26]. Available from:
7. Ridsdale L, Jeffery S, Robins D, McGee L, Fitzgerald A. Epilepsy monitoring and advice recorded: General practitioners' views, current practice and patients' preferences. Br J Gen Pract. 1996;46(402):11-4. PubMed PMID: 8745845.

Competing interests: No competing interests

26 September 2017
Leone Ridsdale
Clinical neurologist, and professor of neurology & general practice
King's College, London
Denmark Hill, London